A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Public ClinicalTrials.gov record NCT06422923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)
Study identification
- NCT ID
- NCT06422923
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Neurona Therapeutics
- Industry
- Enrollment
- 10 participants
Conditions and interventions
Conditions
Interventions
- NRTX-1001 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2024
- Primary completion
- Jun 14, 2027
- Completion
- Jun 14, 2042
- Last update posted
- Jan 6, 2026
2024 – 2042
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | Recruiting |
| University of Southern California Keck Hospital | Los Angeles | California | 90033 | Recruiting |
| UC Irvine Medical Center | Orange | California | 92868 | Recruiting |
| Stanford University | Palo Alto | California | 94304 | Recruiting |
| University of California San Diego | San Diego | California | 92037 | Recruiting |
| University of California San Francisco | San Francisco | California | 94143 | Withdrawn |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Recruiting |
| University of Chicago | Chicago | Illinois | 60637 | Recruiting |
| University of Iowa Health Care | Iowa City | Iowa | 52242 | Recruiting |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | Recruiting |
| Atrium Health | Charlotte | North Carolina | 28204 | Recruiting |
| Duke University Hospital | Durham | North Carolina | 27710 | Recruiting |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | Recruiting |
| Oregon Health and Science University | Portland | Oregon | 97239 | Recruiting |
| UTHealth Houston | Houston | Texas | 77030 | Recruiting |
| UVA Health University Medical Center | Charlottesville | Virginia | 22903 | Recruiting |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06422923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06422923 live on ClinicalTrials.gov.